Dr Westin on the Updated Treatment Paradigm in Second-Line LBCL
Jason R. Westin, MD, director, discusses how the approval of CAR T-cell therapies in the second-line setting has radically shifted preferred treatment approaches in relapsed/refractory large B-cell lymphoma.
Dr. Westin on Subgroup Analysis of ZUMA-7 of Elderly Patients With R/R DLBCL
Jason R. Westin, MD, discusses subgroup analysis of elderly patients treated in the ZUMA-7 trial.
Dr. Westin on the Evolving Landscape of CAR T-Cell Therapy in NHL
Jason R. Westin, MD, discusses the evolving landscape of CAR T-cell therapy in non-Hodgkin lymphoma.
Dr. Westin on the Utilization of CAR T-Cell Therapy in LBCL
Jason R. Westin, MD, director, discusses the utilization of CAR T-cell therapy in relapsed/refractory large B-cell lymphoma.
Concluding Thoughts on the DLBCL Treatment Landscape
DLBCL experts share their thoughts on the changing treatment landscape and emerging treatments in large B-cell lymphomas.
Use of CAR T-Cell Therapies in Earlier Lines of DLBCL
Panelists discuss data on the use of CAR T-cell therapies in earlier lines and implications of these data on the DLBCL treatment landscape going forward.
Monoclonal Antibodies for Treatment of R/R DLBCL
Dr Nowakowski shares data from CD19-targeting monoclonal antibodies in treatment of R/R DLBCL.
Real-World Data With CAR-T Therapies in R/R DLBCL
Dr Westin discusses real-world data with CAR T-cell therapies in R/R DLBCL that were presented at ASH 2021.
Safety With CAR-T Therapies in R/R DLBCL
Dr Maziarz provides an overview of adverse events with CAR T-cell therapies and approaches to managing toxicities.
CAR-T Therapies in R/R DLBCL
Panelists discuss data with CAR T-cell therapies in treatment of relapsed and refractory DLBCL.
Dr Miklos provides an overview of chimeric antigen receptor T (CAR-T) cell therapy.
Refractory vs Relapsed Patients with Diffuse Large B-Cell Lymphoma
Dr Nowakowski discusses patient heterogeneity and treatment of relapsed vs refractory patients with DLBCL.
Dr. Westin on Patient-Reported Outcomes From the TRANSFORM Study in R/R LBCL
Jason R. Westin, MD,discusses the patient-reported outcome data from the phase 3 TRANSFORM study in relapsed/ refractory large B-cell lymphoma.
Dr. Westin on the 2-Year Follow-Up of the TRANSCEND-NHL-001 Trial in R/R LBCL
Jason R. Westin, MD, discusses the 2-year follow-up data of the ongoing phase 1 TRANSCEND-NHL-001 trial in relapsed/refractory large B-cell lymphoma.
Relapsed and Refractory Diffuse Large B-Cell Lymphoma
A panel of diffuse large B-cell lymphoma experts discuss patient criteria and treatment selection in relapsed/refractory DLBCL.
Front-Line Treatment of DLBCL
Drs Westin, Miklos, and other panelists discuss the standard of care and emerging frontline treatments for diffuse large B-cell lymphoma.
Diffuse Large B-Cell Lymphoma Overview: An Aggressive Heterogenous Disease
A panel of oncologists talks about diffuse large B-cell lymphoma, what patient and disease factors one should take into account when thinking about DLBCL.
Dr. Westin on Response Rates in the JULIET Trial for DLBCL
Jason Westin, MD, discusses patient responses with relapsed/refractory diffuse large B-cell lymphoma in the JULIET trial who were treated with tisagenlecleucel.
Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis
Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment
First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma
Data for Luspatercept Highlight Evolving Treatment Landscape in Lower-Risk MDS
2 Clarke Drive Cranbury, NJ 08512